Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-Months follow-up

J. F. Arevalo, L. Wu, J. G. Sanchez, M. Maia, M. J. Saravia, C. F. Fernandez, T. Evans

Research output: Contribution to journalArticlepeer-review

101 Scopus citations


Aims: To study the effects of intravitreal bevacizumab (Avastin) on retinal neovascularization (RN) in patients with proliferative diabetic retinopathy (PDR). Methods: Retrospective study of patients with RN due to PDR who were treated with at least one intravitreal injection of 1.25 or 2.5 mg of bevacizumab. Patients underwent ETDRS best-corrected visual acuity (BCVA) testing, ophthalmoscopic examination, optical coherence tomography (OCT), and fluorescein angiography (FA) at baseline and follow-up visits. Results: Forty-four eyes of 33 patients with PDR and a mean age of 57.2-years (range: 23-82 years) participated in the study. Thirty-three eyes (75%) had previous panretinal photocoagulation (PRP). Twenty-seven eyes (61.4%) showed total regression of RN on fundus examination with absence of fluorescein leakage, 15 eyes (34.1%) demonstrated partial regression of RN on fundus examination and FA. Follow-up had a mean of 28.4 weeks (range from 24 to 40 weeks). BCVA and OCT demonstrated improvement (P<0.0001). Three eyes without previous PRP ('naive' eyes) and with vitreous haemorrhage have avoided vitreo-retinal surgery. One eye (2.2%) had PDR progression to tractional retinal detachment requiring vitrectomy, and one eye (2.2%) had vitreous haemorrhage with increased intraocular pressure (ghost cell glaucoma). No systemic adverse events were observed. Conclusions: Intravitreal bevacizumab resulted in marked regression of RN in patients with PDR and previous PRP, and rapid resolution of vitreous haemorrhage in three naive eyes. Six-months results of intravitreal bevacizumab at doses of 1.25 or 2.5 mg in patients with PDR do not reveal any safety concerns.

Original languageEnglish (US)
Pages (from-to)117-123
Number of pages7
Issue number1
StatePublished - Jan 2009
Externally publishedYes


  • Avastin
  • Bevacizumab
  • Diabetic retinopathy
  • Intravitreal injections
  • Proliferative
  • Retinal neovascularization

ASJC Scopus subject areas

  • Ophthalmology
  • Sensory Systems


Dive into the research topics of 'Intravitreal bevacizumab (avastin) for proliferative diabetic retinopathy: 6-Months follow-up'. Together they form a unique fingerprint.

Cite this